A simple and reliable PCR-restriction fragment length polymorphism assay to identify Candida albicans and its closely related Candida dubliniensis

MEDICAL MICROBIOLOGY

A simple and reliable PCR-restriction fragment length polymorphism assay to identify Candida albicans and its closely related Candida dubliniensis

Yi Ping Ge; Le Wang; Gui Xia Lu; Yong Nian Shen; Wei Da Liu^*

Department of Medical Mycology, Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu Province, China

ABSTRACT

Candida dubliniensis is an emerging pathogen capable of causing superficial as well as systemic infections. Due to its close similarity to C. albcians, conventional methods based on phenotypic traits are not always reliable in identification of C. dubliniensis. In this study, we developed a PCR-restriction fragment length polymorphism (RFLP) assay to identify and discriminate between the two closely related species. The D1/D2 region of 28S rDNA was amplified by PCR and enzymatically digested by ApaI and BsiEI respectively. PCR products of both species were digested into two fragments by ApaI, but those of other yeast species were undigested. BsiEI cut the PCR products of C. albicans into two fragments but not those of C. dubliniensis. Thus two species were differentiated. We evaluated 10 reference strains representing 10 yeast species, among which C. albicans and C. dubliniensis were successfully identified. A total of 56 phenotypically characterized clinical isolates (42 C. albicans isolates and 14 C. dubliniensis isolates) were also investigated for intra-species variability. All tested isolates produced identical RFLP patterns to their respective reference strains except one initially misidentified isolate. Our method offers a simple, rapid and reliable molecular method for the identification of C. albicans and C. dubliniensis.

Key words:Candida albicans, Candida dubliniensis, PCR-restriction fragment length polymorphism, identification, differentiation

INTRODUCTION

Candida species usually reside as commensals at mucosal membranes in healthy individuals and can be detected in approximately 50% of the population in this non-virulent form. However, under conditions when the host's normal flora is disrupted or the immunity is impaired, Candida species often become pathogenic. Candida infections have become a problem of growing significance. The incidence of infections has increased dramatically over the past a few decades. C. albcians is the most common pathogen in this genus and fourth leading cause of nonsocomial bloodstream infections (4, 21). However, several non-albicans Candida species, e.g. C. glabrata, C. tropicalis and C. parapsilosis, have emerged as causative agents of candidiasis (20). Another Candida species of growing clinical importance is C. dubliniensis, a novel opportunistic pathogen first described as a distinct taxon by Sullivan in 1995 (26). C. dubliniensis was mainly associated with oropharyngeal candidiasis in HIV-infected patients. Recent evidence, however, indicates that it is also a cause of superficial and systemic infections in HIV-negative individuals with an estimated prevalence rate below 5% (7, 10, 27). It is important to study the epidemiology of C. dubliniensis due to its capability of rapid acquisition of stable fluconazole resistance, both in vitro and in vivo, after prolonged therapy in HIV-seropositive patients (15, 16, 24).

Identification of C. dubliniensis can be problematic due to its close phenotypic similarity to C. albicans. Both species produces germ tubes, chlamydospores and true hyphae (26). Several phenotypic assays have been developed to differentiate C. dubliniensis from C. albicans, including the capacity to grow at 45ºC, formation of chlamydospores on selected media, the ability to assimilate xylose, lactate or α-methyl-D-glucoside and different colony color produced on CHROMagar Candida medium (2,5,23,28). These assays can serve as rapid methods to screen for potential C. dubliniensis isolates. But none of these assays have proved to be efficient and entirely reliable. At present, the most accurate means of differentiating between these two closely related species requires the use of molecular biology-based techniques, such as electrophoretic karyotyping, DNA fingerprinting analysis with repetitive sequence-containing DNA probes, randomly amplified polymorphic DNA analysis, restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism, conventional and real-time PCR analysis, or pulsed-field gel electrophoresis(18,25). These methods proved very effective. Among them, PCR-RFLP analysis is a simple and reliable one. In this study we developed and evaluated a PCR-RFLP assay to identify and discriminate between C. albicans and C. dubliniensis.

MATERIALS AND METHODS

Yeast Strains

C. albicans (SC 5314), C. dubliniensis (CBS 7987), C. glabrata (ATCC 2001), C. guilliermondii (CBS 6021), C. krusei (ATCC 6258), C. kefyr (CBS 6432), C. lusitaniae (CBS 6936), C. parapsilosis (ATCC 22019), C. tropicalis (CBS 8072) and Trichosporon asahii (CBS 2479) were used as reference yeast strains. Fourteen clinical isolates of presumptive C. dubliniensis originating from sputum (n=10), vaginal swabs (n=3) and urine (n=1) were studied in comparison with 42 clinical strains of C. albicans. Presumptive C. dubliniensis isolates were characterized by phenotypic methods including growth on cornmeal Tween-80 agar, growth at 45ºC, characteristic growth on CHROMagar Candida (CHROMagar, Paris, France) and confirmed by Vitek 2 system (biomerieux, Marcy l'Etoile, France).

Culture Conditions and Genomic DNA Extraction

Yeast cells were cultured on YPD broth (1% yeast extract, 2% peptone, and 2% dextrose) and were incubated for 24-36 hours at 30ºC under shaking conditions (200rpm). The yeast cells were collected by centrifugation(2ml of the broth culture at 12000×g for 2 min), suspended in 600μl of 1 M sorbitol-50 mM phosphate buffer (pH 7.5) containing 50U Lyticase (Sigma-Aldrich, US). After 30 min of incubation at 30ºC, the cells were centrifuged at 1500×g for 10 min. The supernatant was then discarded and pellet was collected. TianGen Yeast Genomic DNA Extraction Kit (TianGen Biotech, Beijing, China) was used to extract genomic DNA from tested isolates by following the enclosed protocol. DNA obtained was finally suspended in 100 μl TE buffer and stored at -20ºC before use.

Sequence Analyses and Selection of Restriction Enzymes

A total of 30 sequences of the 28S ribosomal DNA (rDNA) D1/D2 region of 10 tested yeast species were retrieved from GenBank database (data not shown). Each sequence was then analyzed for restriction sites using the MapDraw program of DNA Star Lasergene Version 7.0. Restriction enzymes were selected as to generate C. albcians-specific and C. dubliniensis-specific RFLP patterns.

PCR Amplification of the D1/D2 region

Primers NL-1 (5'-GCATATCAATAAGCGGAGGAAAAG-3') and NL-4 (5'-GGTCCGTGTTTCAAGACGG-3') were used to amplify D1/D2 region of the 28S rDNA genes. PCR amplifications were carried out in 50-μl volumes containing 1.5μl of each 10μmol/l primer, 25μl of GoTaq Green Master Mix (Promega, Madison, WI, USA), 3μl DNA template and corresponding amount of ultra-pure distilled water. PCR was performed in a PTC-200 DNA Engine thermal cycler (Bio-Rad) with following parameters: 94ºC for 3 min; 94º for 1 min, 52ºC for 30 s and 72ºC for 1 min, repeated for a total of 32 cycles; 72ºC for 10 min and 4ºC hold.

Restriction Digests of PCR Products

RFLP analyses were performed in 20μl volumes with 100-200 ng of amplified DNA products, 25U ApaI or 5U BsiEI(New England Biolabs, Beverly, MA, USA), 2μl 10×digestion buffer, 0.2 µl bovine serum albumin and corresponding amount of water. Digestion mixtures were incubated for 0.5-1 h at 37ºC for ApaI or at 60ºC for BsiEI. The resulting fragments were separated on 2% agarose gels and visualized under UV light after ethidium bromide staining, with a 100bp DNA ladder for fragment size comparison.

RESULT

Sequence Analyses

An extensive analysis of database entries of yeast species tested in this study was performed with respect to calculated fragment lengths of the D1/D2 regions generated by commercially available restriction enzymes. Minor differences in calculated lengths of PCR products were observed. Finally, ApaI and BsiEI were selected to be evaluated in experiment. Predicted fragment lengths of ApaI and BsiEI-digested PCR products are given in Table 1. ApaI was expected to cut the PCR amplicons of C. albicans and C. dubliniensis into two fragments, but leave those of other yeast species intact. BsiEI was selected to digest the amplicon of C. albicans into two fragments and those of C. dubliniensis would remain undigested. Thus two related Candida species can be identified and differentiated by distinctive and specific RFLP patterns.

PCR Amplification of D1/D2 Regions

As shown in Fig.1, intended DNA fragments of all reference strains were successfully amplified with primers NL-1 and NL-4. PCR products were found to reach 550-600 bp in length as predicted from sequence analysis. However, most tested species, except C. lusitaniae, were inseparable due to similar PCR amplicon sizes.

RFLP Analyses of Reference Strains

When digested with ApaI, D1/D2 regions of C. albicans and C. dubliniensis strains shared the same restriction pattern, with two bands of almost identical sizes (134bp, 481bp for C. albicans and 134bp, 480bp for C. dubliniensis) (Fig.2). Nevertheless, amplicons of other yeast strains were undigested by ApaI, which easily distinguished C. albicans and C. dubliniensis from other tested species. Digestion of the D1/D2 region with BsiEI generated distinctive restriction profiles for C. albicans: two fragments of 181bp and 434bp (Fig.3). In addition, BsiEI also cut into two fragments the PCR-products of C. glabrata (149bp and 475bp), C. krusei (59bp and 548bp) and C. lusitaniae (126bp and 433bp). As was seen in Fig.3, the differences in fragment lengths were sufficient to discriminate C. albicans from C. glabrata, C. krusei and C. lusitaniae. Other tested species were undigested by BsiEI, including C. dubliniensis. Therefore, two separate enzymatic digestions produced species-specific RFLP profiles for C. albicans and C. dubliniensis.

Evaluation for Intra-species Variation of Restriction Sites

To assess intra-species variability of the two restriction sites, a total of 56 clinical isolates of C. albicans and C. dubliniensis were also investigated. Most tested isolates, after digestion with ApaI and BsiEI respectively, showed identical and consistent RFLP patterns to their respective reference strains (data not shown). However, one of the 14 presumptive C. dubliniensis isolates showed RFLP pattern indicative of C. albicans. Further sequencing of the D1/D2 region of this isolate confirmed the identification of C. albicans.

DISCUSSION

Rapid and accurate identification of C. dubliniensis is crucial for the study of epidemiology and clinical management of infections caused by this opportunistic pathogen. However, this is hampered by lack of easy and reliable methods for definite identification. Most phenotypic methods are presumptive and often subject to error (28). Although several commercial identification systems such as Vitek 2 system, have demonstrated useful in separation of C. albicans and C. dubliniensis, results are not always reliable as was seen in our study (3, 12, 23). Confirmatory identification of C. dubliniensis always requires the molecular methods.

PCR-RFLP assays have been successfully applied to the identification of Candida species (17, 22, 29). Compared with other molecular methods, PCR-RFLP analysis is generally easy and rapid to perform. Although more complex RFLP methods have previously been used for the identification of C. dubliniensis, their use may be limited since they were time-consuming or the results were difficult to interpret (18).Thus in this study, simpler but more advantageous PCR-RFLP is preferred due to its increased applicability in clinical laboratories.

Ribosomal regions, such as the internal transcribed spacer (ITS) region and 28S rDNA, exhibit a low intraspecific polymorphism and a high interspecific variability, making them ideal targets for species identification purposes (9). In this study, we selected the D1/D2 variable region at the 5' end of the 28S rDNA gene as target for PCR amplification. Sequencing of this region has been demonstrated to be sufficient for accurate identification of most yeast species (11). Between C. albicans and C. dubliniensis, there are 13 nucleotide differences in the region D1/D2, sufficiently variable for reliable differentiation. Two enzymes, ApaI and BsiEI, were selected based on the restriction profiles generated by these nucleotide differences. Despite that only a limited number of C. albicans and C. dubliniensis isolates were investigated, those restriction sites for ApaI and BsiEI seemed to be well conserved in these two species.

Several PCR-RFLP assays have been described so far to discriminate between C. albicans and C. dubliniensis (Table 1). Irobi et al amplified the ITS regions (ITS1, 5.8S, ITS2) of several medically important Candida species, including C. dubliniensis (8). Further RFLP analysis with BfaI, DdeI or HaeIII revealed distinct differences between the two species. McCullough et al amplified the ITS regions and restricted them with DdeI. C. albicans produced one fragment while C. dubliniensis produced two fragments (13). In the same study, McCullough and his group also targeted the V3 region of 25S/28S rDNA and cut the PCR amplicons with HaeIII; the discrimination could be made based on fragments of different sizes. Park and his co-authors amplified a conserved part of the 5.8S rDNA, the adjacent ITS2 region and a part of 28S rDNA. The differentiation was achieved by analysis of the PCR products with BsmAI (C. dubliniensis-specific) and NspBIII (C. albicans-specific) (19). Three other PCR-RFLP assays also used a similar strategy by targeting a part or whole of the ITS region (1, 6, 14). All these methods proved effective for accurate identification. In comparison, our study used a slightly different strategy. We first identified a restriction site for ApaI which was specific to both species, instantly separating them from other yeast species. Subsequently BsiEI was found to produce C. albicans specific pattern and C. dubliniensis was identified by absence of the restriction site.

An advantage of the method described here is the stable and easy-to-read RFLP patterns. Unlike previous reports, this method involves only one or two DNA fragments. Besides, it is a simple and rapid method to perform. With the aid of time-saving restriction enzymes, the whole process can be accomplished in less than 6h, requiring no sophisticated equipments except a conventional thermal cycler. Considering that DNA sequencer may not be readily available to most clinical laboratories, this molecular method is applicable for unequivocal identification and differentiation of C. albicans and C. dubliniensis.

ACKNOWLEDGEMENTS

The authors report no conflicts of interest.

Submitted: December 02, 2010; Returned to authors for corrections: May 05, 2011; Approved: June 07, 2012.

• 1. Ahmad, S.; Khan, Z.; Mokaddas, E.; Khan, Z.A. (2004). Isolation and molecular identification of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Kuwait. J Med Microbiol. 53(Pt7): 633637.
• 2. Akgül, O.;Cerikçioğlu, N. (2009). Hypertonic sabouraud dextrose agar as a substrate for differentiation of Candida dubliniensis Mycopathologia 167(6):357-359.
• 3. Cárdenes-Perera, C.D.; Torres-Lana, A.; Alonso-Vargas, R.; Moragues-Tosantas, M.D.; Pontón-San Emeterio, J.;Quindós-Andrés, G.; Arévalo-Morales, M.P. (2004). Evaluation of API ID 32C and Vitek-2 to identify Candida dubliniensis. Diagn Microbiol Infect Dis. 50(3): 219221.
• 4. Edmond, M.B.; Wallace, S.E.; McClish, D.K.; Pfaller, M.A.; Jones, R.N.; Wenzel, R.P. (1999). Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infec Dis 29(2): 239-244.
• 5. Gales, A.C.; Pfaller, M.A.; Houston, A.K.; Joly, S.; Sullivan, D.J.; Coleman, D.C.; Soll, D.R. (1999). Identification of Candida dubliniensis based on temperature and utilization of xylose and α-methyl-D-glucoside as determined with the API 20C AUX and Vitek YBC systems. J Clin Microbiol 37(12): 38043808.
• 6. Graf, B.; Trost, A.; Eucker, J.; Göbel, U.B.; Adam, T. (2004). Rapid and simple differentiation of C. dubliniensis from C. albicans Diagn Microbiol Infect Dis 48(2): 149151.
• 7. Gutierrez, J.; Morales, P.; Gonzalez, M.A.; Quindos, G. (2002). Candida dubliniensis, a new fungal pathogen. J Basic Microbiol 42(3): 207227.
• 8. Irobi, J.; Schoofs, A.; Goossens, H. (1999). Genetic identification of Candida species in HIV-positive patients using the polymerase chain reaction and restriction fragment polymorphism analysis of its DNA. Mol Cell Probes 13(6): 401406.
• 9. Iwen, P.C.; Hinrichs, S.H.; Rupp, M.E. (2002). Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens. Med Mycol, 40(1): 87-109.
• 10. Jewtuchowicz, V.M.; Mujica, M.T.; Brusca, M.I.; Sordelli, N.; Malzone, M.C.; Pola, S.J.; Iovannitti, C.A.; Rosa, A.C. (2008). Phenotypic and genotypic identification of Candida dubliniensis from subgingival sites in immunocompetent subjects in Argentina. Oral Microbiol Immunol 23(6): 505509.
• 11. Kurtzman, B.P.; Robnett, C.J. (1997). Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 50 end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol 35(5): 12161223.
• 12. Mähnss, B.; Stehr, F.; Scäfer, W.; Neuber, K. (2005). Comparison of standard phenotypic assays with a PCR method to discriminate Candida albicans and C. dubliniensis. Mycoses. 48(1): 5561.
• 13. McCullough, M.J.; Clemons, K.V.; Stevens, D.A. (1999). Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea J Clin Microbiol 37(2): 417421.
• 14. Mirhendi, H.; Makimura, K.; Khoramizadeh, M.; Yamaguchi, H. (2006). A one-enzyme PCR-RFLP assay for identification of six medically important Candida Species. Nippon Ishinkin Gakkai Zasshi 47(3): 225-229.
• 15. Moran, G.P.; Sanglard, D.; Donnelly, S.M.; Shanley, D.B.; Sullivan, D.J.; Coleman, D.C. (1998). Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis Antimicrob Agents Chemother 42(7): 1819-1830.
• 16. Moran, G.P.; Sullivan, D.J.; Henman, M.C.; McCreary, C.E.; Harrington, B.J.; Shanley, D.B.; Coleman, D.C. (1997). Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob Agents Chemother 41(3): 617-623.
• 17. Mousavi, S.A.A.; Khalesi, E.; Shahidi Bonjar, G.H.; Aghighi, S.; Shaifi, F.; Aram, F. (2007). Rapid molecular diagnosis for Candida species using PCR-RFLP. Biotechnology 6(4):583-587.
• 18. Neppelenbroek, K.H.; Campanha, N.H.; Spolidorio, D.M.P.; Spolidorio, L.C.; Seó, R.S.; Pavarina, A.C. (2006). Molecular fingerprinting methods for the discrimination between C. albicans and C. dubliniensis. Oral Disease.12 (3): 242253.
• 19. Park, S.; Wong, M.; Marras, S.A.E.; Cross E.W.; Kiehn T.E.; Chaturvedi V.; Tyagi, S.; Perlin D.S. (2000). Rapid identification of Candida dubliniensis using a species-specific molecular probe. J Clin Microbiol 38(8): 28292836.
• 20. Pfaller, M.A.; Diekema, D.J. (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clin Micobio Rev 20(1): 133-163.
• 21. Pfaller, M.A.; Jones, R.N.; Messer, S.A.; Edmond, M.B.; Wenzel, R.P. (1998) National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 31(1): 327-332.
• 22. Pinto, P.M.; Resende, M.A.; Koga-Ito C.Y.; Ferreira, J.A.; Tendler, M. (2004). rDNA-RFLP identification of Candida species in immunocompromised and seriously diseased patients. Can J Microbiol 50(7):514-520.
• 23. Pincus, D.H.; Coleman, D.C.; Pruitt, W.R.; Padhye, A.A.; Salkin, I.F.; Geimer, M.;Bassel, A.; Sullivan, D.J.; Clarke, M.; Hearn, V. (1999). Rapid identification of Candida dubliniensis with commercial yeast identification systems. J Clin Microbiol 37(11):35333539.
• 24. Ruhnke, M.; Schmidt-Westhausen, A.; Morschhauser, J. (2000). Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patient with AIDS. J Antimicrob Chemother 46(2): 291-295.
• 25. Rocha, B.A.; Barbaro Del Negro G.M.; Yamamoto, L.; de Souza, M.V.B.; Precioso, A.R.; Okay, T.S. (2008). Identification and differentiation of Candida species from paediatric patients by random amplified polymorphic DNA. Rev Soc Bras Med Trop 41(1): 15.
• 26. Sullivan, D.J.; Westerneng, T.J.; Haynes, K.A.; Bennett, D.E.; Coleman, D.C. (1995). Candida dubliniensis sp. nov.: phenotypic and molecular characterisation of a novel species associated with oral candidosis in HIV infected individuals. Microbiology 141(7): 15071521.
• 27. Sullivan, D.J.; Coleman, D.C. (1998). Candida dubliniensis: characteristics and identification. J Clin Microbiol 36(2): 329334.
• 28. Tintelnot, K.; Haase, G.; Seibold, M.; Bergmann, F.; Staemmler, M.; Franz, T.; Naumann, D. (2000). Evaluation of phenotypic markers for selection and identification of C. dubliniensis J Clin Microbiol 38(4):15991608.
• 29. Trost, A.; Graf, B; Eucker, J.; Sezer, O.; Possinger, K.; Göbel, U.; Adam, T. (2004).  Identification of clinically relevant yeasts by PCR/RFLP. J Microbio Methods 56(2): 201-211.

Publication Dates

• Publication in this collection
  26 Nov 2012
• Date of issue
  Sept 2012

History

• Received
  02 Dec 2010
• Accepted
  07 June 2012
• Reviewed
  05 May 2011